Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SB 1800Sesión 2025

Qué cambió entre versiones

112 párrafos cambiaron+309 palabras agregadas−284 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

Florida Senate

-

2025

CS for CS for SB 1800

By

the Appropriations Committee on Health and Human Services;

the Committee on Health Policy; and Senator Calatayud

588-03164-25603-03438-25 20251800c120251800c2

1 A bill to be entitled

5 párrafos sin cambios

2 An act relating to Parkinson’s disease; creating s.

3 1004.4352, F.S.; providing a short title; providing

4 legislative findings; defining terms; establishing the

5 Consortium for Parkinson’s Disease Research within the

6 University of South Florida; establishing the

7 Parkinson’s Disease Research Board; providing for the

8 membership and duties of the board; requiring the board to direct

9 board to direct the operations of the consortium and to annually adopt;

10 aproviding planduties forof Parkinson’sthe diseaseconsortium researchdirector; providing

11 research requirements for the plan; requiring the

12 board to award funds to board members for certain

1113 dutiespurposes; ofrequiring the consortiumboard director;to providingissue researchan annual

12 requirements for the plan; requiring the board to

13 award funds to board members for certain purposes;

14 requiring the board to issue an annual report to the

1514 report to the Governor and Legislature by a specified date;

1615 date; providing appropriations; providing an effective date.

16 date.

17

50 párrafos sin cambios

18 Be It Enacted by the Legislature of the State of Florida:

19

20 Section 1. Section 1004.4352, Florida Statutes, is created

21 to read:

22

1004.4352

Parkinson’s disease research.—

23

(1)

SHORT TITLE.—This section may be cited as the

24

“Parkinson’s Disease Research Act.”

25

(2)

LEGISLATIVE FINDINGS.—The Legislature finds that:

26

(a)

Parkinson’s disease is a progressive neurological

27

disorder affecting approximately one million Americans, with an

28

estimated 90,000 new diagnoses each year.

29

(b)

Currently, there is no cure for Parkinson’s disease,

30

and innovative research is essential to advance therapies,

31

improve patient outcomes, and alleviate the burden of the

32

disease.

33

(3)

DEFINITIONS.—As used in this section, the term:

34

(a)

“Board” means the Parkinson’s Disease Research Board.

35

(b)

“Consortium” means the Consortium for Parkinson’s

36

Disease Research.

37

(4)

CONSORTIUM FOR PARKINSON’S DISEASE RESEARCH.—

38

(a)

There is established within the University of South

39

Florida the Consortium for Parkinson’s Disease Research which

40

shall consistbe composed of public and private universities. The purpose ofand

41

the consortium is to conduct rigorous scientific research and

academic medical centers. The purpose of the consortium is to

42

disseminate such research.

conduct rigorous scientific research and disseminate such

43

research.

44

(b)

The Parkinson’s Disease Research Board is established

4445

to direct the operations of the consortium. The board shall be

4546

composed of members representing each participating university

46

and appointed by the president of each participating university.

47

Board members must have experience in a variety of scientific

or academic medical center, appointed by the president or chief

48

fields, including, but not limited to, neurology, psychology,

executive officer, respectively, of each participating

49

nutrition, and genetics. Members shall be appointed to 4-year

university or academic medical center. Board members must,

50

terms and may be reappointed to serve additional terms. The

collectively, have experience in a variety of scientific fields,

51

chair shall be elected by the board from among its members to

including, but not limited to, neurology, psychology, nutrition,

52

serve a 2-year term. The board shall meet at least semiannually

and genetics. Members shall be appointed to 4-year terms and may

53

at the call of the chair or, in his or her absence or

be reappointed to serve additional terms. The chair shall be

54

incapacity, the vice chair. Four members constitute a quorum. A

elected by the board from among its members to serve a 2-year

55

majority vote of the members present is required for all actions

term. The board shall meet at least semiannually at the call of

56

of the board. The board may prescribe, amend, and repeal a

the chair or, in his or her absence or incapacity, the vice

57

charter governing the manner in which it conducts its business.

chair. Four members constitute a quorum. A majority vote of the

58

Board members shall serve without compensation, but are entitled

members present is required for all actions of the board. The

59

to receive reimbursement for travel expenses by the consortium

board may prescribe, amend, and repeal a charter governing the

60

or the organization he or she represents in accordance with s.

manner in which it conducts its business. Board members shall

61

112.061.

serve without compensation, but are entitled to receive

62

reimbursement for travel expenses by the consortium or the

63

organization he or she represents in accordance with s. 112.061.

64

(c)

The consortium shall be administered by a director, who

6365

shall be appointed by and serve at the pleasure of the board.

6466

The director shall, subject to the approval of the board:

6567

1.

Propose a budget for the consortium.

6668

2.

Foster the collaboration of scientists, researchers, and

6769

other appropriate personnel in accordance with the consortium’s

68

70

charter.

69

71

3.

Engage individuals in public and private university and

70

programs relevant to the consortium’s work to participate in the

71

consortium.

72

academic medical center

programs relevant to the consortium’s

73

work to participate in the consortium.

74

4.

Identify and prioritize the research to be conducted by

7375

the consortium.

7476

5.

Prepare a plan for Parkinson’s disease research for

7577

submission to the board.

7678

6.

Apply for grants to obtain funding for research

7779

conducted by the consortium.

7880

7.

Perform other duties as determined by the board.

79

81

(d)

The board shall annually adopt a plan for Parkinson’s

8082

disease research. The plan must organize a program of research

8183

that contributes to the body of scientific knowledge on the

8284

causes, mechanisms, and potential treatments for Parkinson’s

8385

disease and the prevalence of Parkinson’s disease in first

8486

responders. The board must award funds to members of the

8587

consortium to perform research consistent with the plan.

8688

(e)

By October 15 of each year, the board shall issue a

8789

report to the Governor, the President of the Senate, and the

88

90

Speaker of the House of Representatives on research projects,

8991

research findings, community outreach initiatives, and future

9092

plans for the consortium.

9193 Section 2.

(1)

Subject to appropriations from the General

9294

Appropriations Act, 67

percent

of funds

appropriated are

9395

directed to the University of South Florida for Parkinson’s

9496

disease research including, but not limited to, identifying the

9597

genetic origin of the disease and developing therapeutic

9698

interventions to slow or stop the progression of the disease.

9799

(2)

Subject to appropriations from the General

98

100

Appropriations Act, 33

percent

of funds appropriated

are

99

101

directed to the University of South Florida for the Consortium

100102

for Parkinson’s Disease Research.

101103 Section 3. This act shall take effect July 1, 2025.

Volver al texto completo